[REGN] Regeneron: Q3 2026 earnings preview on the Dupixent profit step-up and EYLEA HD

Regeneron is a U.S. biotechnology company that discovers, develops, manufactures and sells antibody medicines, and its earnings calendar has it reporting third-quarter 2026 results, covering July 1 to September 30, 2026 (2026 年三季度(2026 年 7 月 1 日至 9 月 30 日)), with a conference call on 2026-10-30[1]. In the latest disclosed period, the second quarter of 2026, revenue rose 17% to $4.29 billion; Dupixent global sales, recorded by Sanofi, rose 38% to $5.998 billion; U.S. EYLEA HD sales rose 52% to $596 million; GAAP EPS was $12.23 and non-GAAP EPS was $14.29[2]. The company does not guide revenue or EPS. In July it narrowed full-year GAAP R&D guidance to $6.500 billion to $6.635 billion and raised its GAAP gross margin on net product sales range to 78%-79%[3], and in October it disclosed that the third quarter will include an acquired in-process R&D charge of about $22 million, reducing EPS by about $0.18[4]. As of October 16, the consensus of 12 analysts for third-quarter revenue was $4.55 billion and the consensus of 14 analysts for EPS was $16.07, both above the second-quarter actuals[5].

Three things matter in the Regeneron Q3 2026 earnings report. First, Regeneron had repaid all of the development costs Sanofi advanced by the end of the second quarter, so the $253 million deducted from collaboration profit in that quarter no longer applies from the third quarter[6]; the question is whether that amount shows up in full in collaboration revenue while Dupixent keeps growing from a higher base. Second, EYLEA HD has outsold the original EYLEA in the U.S. for the first time, but more EYLEA biosimilars are about to launch in the U.S.[7], so the question is whether EYLEA HD conversion can absorb the revenue EYLEA is losing. Third, the Limerick bulk drug plant has returned to normal production[8] and collaboration profit is stepping up, while full-year expense guidance implies higher R&D and SG&A in the second half, so the question is whether third-quarter operating income clearly exceeds the second quarter's $1.29 billion[9]. These three points determine whether Regeneron's largest revenue source, its largest self-sold product line and its margins improve together.

Company Background and Business Structure

Regeneron runs the full chain from discovery to commercialization of antibody drugs, and its profit and cash flow over the next several years rest mainly on two products, EYLEA HD and Dupixent. The company was incorporated in New York in 1988, is headquartered in Tarrytown, and develops products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological, hematologic and rare diseases[10]. At the end of 2025 it had 15,410 full-time employees, including 11,961 in the U.S. and 2,149 in Ireland[11]; its owned plants in Rensselaer, New York and Limerick, Ireland have about 100,000 and 120,000 liters of cell culture capacity[12]. The annual report states plainly that the company's ability to generate profits and operating cash flow over the next several years depends significantly on commercializing EYLEA HD and Dupixent[13].

Regeneron reports a single segment, but its revenue comes from three economic arrangements that readers need to separate. Total 2025 revenue was $14.34 billion, of which net product sales recorded by Regeneron itself were $6.31 billion[14], mainly U.S. EYLEA HD ($1.637 billion) and EYLEA ($2.748 billion), plus global sales of the PD-1 antibody Libtayo ($1.452 billion)[15]; Libtayo also carries a 2.5% royalty to Sanofi through the end of 2026[16]. These products are sold mostly to wholesalers and specialty distributors, and in 2025 the two largest customers accounted for 50% and 27% of gross product revenue[17], before retina specialists inject the drugs in the office and bill payers such as Medicare.

Collaboration revenue is Regeneron's largest revenue source, and it is a profit share rather than a sales figure. Sanofi records global sales of Dupixent and Kevzara, which totaled $18.38 billion in 2025; Regeneron's share of profits was $6.171 billion, of which it recognized $5.242 billion after the contractual repayment of development costs Sanofi had advanced, and with $642 million of manufacturing reimbursement total Sanofi collaboration revenue was $5.884 billion[18]. The partners split U.S. profits equally, while Regeneron's share outside the U.S. runs from 35% to 45% depending on sales[19]. Bayer records EYLEA franchise sales outside the U.S., which were $3.506 billion in 2025; the partners share those profits equally, and Regeneron recognized $1.422 billion of Bayer collaboration revenue[20]. The remaining $703 million of other revenue is mainly Ilaris royalties, ARCALYST profit share and contract manufacturing[14].

The cost structure maps onto these three revenue types, so a dollar of revenue does not contribute the same profit in each. Cost of goods sold covers only self-sold products, while the cost of manufacturing for partners is reported separately as cost of collaboration and contract manufacturing; R&D was $5.85 billion in 2025, the largest expense line[21]. On collections, self-sold products are paid on wholesaler terms and collaboration profit is settled quarterly by Sanofi and Bayer, with $2.272 billion due from Sanofi at the end of June 2026[19].

Financial History and Current Position

Regeneron's revenue was nearly flat from 2023 to 2025 while operating income fell every year. Revenue rose from $13.12 billion in 2023 to $14.20 billion in 2024 and $14.34 billion in 2025, but operating income dropped from $4.047 billion to $3.991 billion and then $3.578 billion[14]. Revenue stalled because net product sales fell from $7.629 billion in 2024 to $6.309 billion in 2025, including a $2.019 billion drop in U.S. EYLEA, offset only by Sanofi collaboration revenue rising from $4.531 billion to $5.884 billion[14]. The profit decline came from both ends: R&D rose from $4.439 billion in 2023 to $5.850 billion in 2025[21], and the gross margin on net product sales fell from 87% to 82%[22].

Net income in 2025 was higher than operating income, supported mainly by non-operating gains. Net income was $4.505 billion, or $41.48 per diluted share, with $1.653 billion of other income[14], most of it from $946 million of gains on marketable securities and $717 million of interest income. In 2025 operating cash flow was $4.979 billion, capital expenditures were $898 million and share repurchases were $3.439 billion[23].

Revenue returned to double-digit growth in the first half of 2026, and most of the increase came from Sanofi. First-quarter revenue rose 19% to $3.605 billion[24]; second-quarter revenue rose 17% to $4.291 billion, including Sanofi collaboration revenue up 51% to $2.174 billion, U.S. EYLEA HD up 52% to $596 million, U.S. EYLEA down 45% to $412 million and global Libtayo up 30% to $489 million[25]. Second-quarter GAAP operating income was $1.294 billion, up from $1.080 billion a year earlier[9]; the GAAP gross margin on net product sales was 78% against 87% non-GAAP, a gap driven mainly by costs related to the Limerick bulk production interruption[8]. Second-quarter GAAP EPS was $12.23 and non-GAAP EPS was $14.29, with $127 million of acquired in-process R&D reducing non-GAAP EPS by about $0.99[2].

The balance sheet is very strong, but operating cash flow fell year over year in the first half. Operating cash flow in the first half of 2026 was $1.892 billion, down from $2.190 billion a year earlier, mainly because receivables rose[26]; capital expenditures were $471 million and free cash flow was $1.421 billion[27]. The company repurchased $2.0 billion of stock in the first half and raised its quarterly dividend to $0.94 per share[28]. At the end of June it held $17.82 billion of cash and marketable securities and $6.565 billion of receivables[28], against $1.987 billion of long-term debt[26]. The Sanofi development balance stood at about $595 million at the end of 2025[29], and after deductions of $277 million in the first quarter and $253 million in the second quarter it was fully repaid[6].

Operating Model

Regeneron's revenue is the sum of self-sold net product sales, collaboration revenue and other revenue, and collaboration revenue has the most direct driver. Net product sales are recognized when wholesalers receive product, net of rebates, discounts and distribution fees; Sanofi collaboration revenue equals Regeneron's share of global Dupixent and Kevzara profits minus development balance deductions plus manufacturing reimbursement; Bayer collaboration revenue equals half of EYLEA franchise profits outside the U.S. minus development deductions plus manufacturing reimbursement[30]. In the second quarter, net product sales were $1.642 billion, Sanofi $2.174 billion, Bayer $276 million and other revenue $193 million, for a total of $4.291 billion[25]. Dupixent alone contributes about half of revenue, and it is already profit when recognized.

Operating income responds to Dupixent and EYLEA in opposite directions and at different speeds. Sanofi collaboration revenue has no matching cost of sales, because Sanofi's costs are deducted before the profit split, so Dupixent growth falls almost entirely, and in the same quarter, to operating income[18]. EYLEA erosion from biosimilars removes high-margin self-sold revenue directly; in 2025 the gross margin on net product sales was 82% and the operating margin about 24.9%[22]. In the second quarter the operating margin was about 30.1%, with R&D of $1.632 billion, SG&A of $662 million and cost of goods sold of $361 million[8].

Cash flow is driven mainly by the timing of receivables, while capital spending and shareholder returns are backed by a large cash reserve. Self-sold products go to wholesalers, and two customers accounted for 87% of net trade receivables at the end of 2025[17]; Sanofi and Bayer settle profit shares quarterly, and with Dupixent growth and the repaid development balance the amount due from Sanofi rose from $1.611 billion at the start of the year to $2.272 billion at the end of June[19]. The company lowered its 2026 capital expenditure guidance to $1.030 billion to $1.100 billion, mainly for R&D facilities and a new manufacturing site[26], and it also carries a $720 million headquarters finance lease[31]. As collaboration profit steps up, the receivable from Sanofi therefore grows with it, and the improvement in operating cash flow may lag revenue recognition.

Industry and Competitive Position

Regeneron's competitive position differs sharply across ophthalmology, immunology and oncology. In ophthalmology, EYLEA's U.S. regulatory exclusivity expired in May 2024, Amgen's biosimilar Pavblu launched in the U.S. in the fourth quarter of 2024, and Roche's Vabysmo is also competing for share[32], while some patients have moved to compounded bevacizumab because of affordability constraints[33]. U.S. EYLEA sales fell 42% in 2025, the annual report anticipates more EYLEA biosimilars launching in the U.S. in the second half of 2026[34], and the settlement with Samsung only keeps its product out until January 2027[35].

Regeneron's response in ophthalmology is to move patients to EYLEA HD, which has longer dosing intervals. In April 2026 the FDA approved EYLEA HD dosing up to every 20 weeks[36]; in the second quarter EYLEA HD made up about 60% of U.S. retinal sales, up from about 34% a year earlier[37]. The limit of this position is that EYLEA HD has no U.S. regulatory exclusivity, and approval of its pre-filled syringe has been delayed twice, which still weighs on clinics' willingness to switch[38].

In immunology, Dupixent is Regeneron's most competitive asset, but it also faces several drugs with new mechanisms. Dupixent's indications span atopic dermatitis, asthma, nasal polyps, COPD, eosinophilic esophagitis and chronic urticaria, and its competitors include JAK inhibitors and antibodies against IL-13, IL-31R, TSLP and OX40(L)[32]. In October 2026 the partners signed a Sixth Amendment that adds four long-acting Regeneron-invented IL-13, IL-4 and IL-4Rα antibodies to the collaboration, with Sanofi paying a $1.0 billion upfront payment[4].

In oncology, Libtayo is smaller but growing faster, and overall Regeneron's revenue remains highly concentrated. Libtayo competes with PD-1 and PD-L1 antibodies such as Keytruda and Opdivo[32], and in the second quarter it captured 20% of new-to-brand prescriptions in first-line non-small cell lung cancer in the U.S.[37]. Compared with biotechnology companies that rely on one product, Regeneron's revenue sources are broader, but in 2025 Sanofi collaboration revenue and the EYLEA franchise (U.S. sales plus the Bayer share outside the U.S.) still made up about 81% of total revenue[14]. This comparison can cover only product sales and share, not competitors' profit structures, because Sanofi records Dupixent's costs.

Core Debates

Regeneron has repaid the last of the development costs Sanofi advanced on Dupixent. Starting in the third quarter, a deduction of roughly $250 million a quarter disappears. Will that flow fully into Regeneron's collaboration revenue while Dupixent keeps growing off a higher base?

This debate matters because Sanofi collaboration revenue is already half of Regeneron's total revenue and carries almost no matching cost. Second-quarter Sanofi collaboration revenue was $2.174 billion, or 50.7% of revenue[25]; under the agreement, Regeneron only had to apply up to 20% of its quarterly profit share to repaying the development balance[29]. The deduction was $930 million in 2025 and another $530 million in the first half of 2026[6], and it stops from the third quarter. That makes it the most certain source of profit growth in the second half of 2026, and it roughly explains why the third-quarter revenue consensus is about $260 million above the second quarter[5].

Current evidence shows Dupixent still growing fast and Regeneron's share rising. Second-quarter Dupixent global sales rose 38% to $5.998 billion, including $4.561 billion in the U.S.[39]; Dupixent and Kevzara together reached $6.204 billion, Regeneron's share before the deduction was $2.286 billion, or 36.8%, above 34.4% in the first quarter and 33.6% for 2025, and after the $253 million deduction it recognized $2.033 billion, up 59%[6]. The CFO said the repayment will drive a meaningful step-up in collaboration profits beginning in the third quarter[40], consistent with what management said on the first-quarter call[41]; management also cautioned that Dupixent's year-over-year growth will moderate in the second half as new indications annualize and comparisons get tougher[42].

The transmission chain is short, but the profit-share ratio and the growth rate both remain uncertain. Dupixent uptake in new indications such as COPD, chronic urticaria, bullous pemphigoid and allergic fungal rhinosinusitis lifts the global sales Sanofi records; after costs and shared commercialization expenses this becomes collaboration profit, of which Regeneron takes 50% in the U.S. and 35% to 45% abroad, and with no development deduction the full share enters collaboration revenue and falls almost entirely to operating income[19]. An alternative reading is that the 36.8% share in the second quarter contained one-off factors, and that heavier Sanofi commercial spending or a rising ex-U.S. mix in the second half pulls it back toward 34%, in which case the end of the deduction only partly offsets slower growth. The October Sixth Amendment kept the existing profit split unchanged and, through a settlement, ended Regeneron's lawsuit over access to Dupixent information and audit rights[4], but how development costs for the new antibodies are shared has not yet appeared in the financial statements.

Whether the third-quarter report confirms the step-up depends on three numbers appearing together. If Regeneron's recognized Sanofi profit share is at least $2.286 billion, Dupixent global sales grow at least 30% year over year, the pre-deduction share stays above 35% and the development deduction is zero, the step-up has been realized in full. Conversely, a profit share below the second quarter's $2.033 billion would mean the benefit of the removed deduction has been offset by slower Dupixent growth or higher costs, and a share falling below 34% would mean Dupixent growth is converting into Regeneron profit less efficiently.

EYLEA HD has outsold the original EYLEA in the U.S. for the first time. With more EYLEA biosimilars about to launch, can EYLEA HD conversion in the third quarter keep pace with the revenue EYLEA is losing?

This debate matters because the U.S. EYLEA franchise is still Regeneron's largest self-sold product line and carries a high margin. In 2025 U.S. EYLEA HD and EYLEA together were $4.385 billion, about 31% of total revenue[15]; U.S. EYLEA sales fell by about $2 billion in 2025 and declined 41% in the first half of 2026[7]. If EYLEA HD cannot fill the gap, net product sales will keep dragging on operating income and offset growth in Dupixent collaboration profit.

Current evidence shows EYLEA HD accelerating, but inventory noise separates demand from net sales. Second-quarter U.S. EYLEA HD sales were $596 million, up 52% year over year and 27% sequentially, primarily on higher volumes partly offset by a lower net price; U.S. EYLEA sales fell 45% to $412 million because of competition, conversion to EYLEA HD and a lower net price[43]. On second-quarter figures EYLEA HD was about 59.1% of the U.S. franchise, against 49.7% in the first quarter[39]. In the first quarter EYLEA HD net sales fell 7% sequentially even though physician unit demand rose 10%, the difference reflecting wholesaler inventory[44]. Outside the U.S., sales recorded by Bayer fell 32% to $666.5 million and Regeneron's profit share fell 41% to $227 million[45].

The uncertainty in this chain is how much of the strong sequential growth in the second quarter was inventory rebuilding. After EYLEA lost exclusivity, biosimilars, Vabysmo and compounded bevacizumab took patients, retina specialists moved patients still on Regeneron products to EYLEA HD, and U.S. net product sales shifted between the two, directly affecting high-margin self-sold revenue; the same competition abroad reaches collaboration revenue through the Bayer share. Management said EYLEA HD unit demand should grow sequentially in the low to mid-teens in the third and fourth quarters, while EYLEA demand should decline sequentially by a similar low to mid-teens rate[42]. An alternative reading is that part of the 27% sequential gain in the second quarter was restocking after the first-quarter destocking, that true demand growth is closer to 10%, and that EYLEA losses accelerate once more biosimilars launch so the combined U.S. franchise declines again. Approval of the pre-filled syringe has not arrived either; the company has engaged more than two contract fillers and targets approval by year-end[46].

The third-quarter report needs to be read through EYLEA HD sequential growth, the EYLEA decline and the franchise total together. If U.S. EYLEA HD net sales grow at least 10% sequentially, to about $656 million or more, EYLEA's sequential decline stays within 15%, the franchise total is at least $1.009 billion and EYLEA HD's share rises above 63%, conversion is keeping pace[25]. Sequential EYLEA HD growth below 5% would mean conversion is falling behind EYLEA losses, and a sequential EYLEA decline above 20% would mean the biosimilar impact is arriving earlier than anticipated. Whether new biosimilars have launched in the U.S., progress on the pre-filled syringe and whether the Bayer share holds near $227 million are signals to record at the same time.

The end of the Dupixent profit deduction and lower acquired R&D give Regeneron roughly $360 million of tailwind in the third quarter, while guidance implies higher R&D and SG&A in the second half. Will third-quarter operating income rise by the full amount of that step-up?

This debate matters because it decides whether the collaboration step-up becomes profit growth or is absorbed by pipeline spending. Regeneron's revenue was nearly flat from 2023 to 2025 while operating income fell from $4.047 billion to $3.578 billion[14], mainly because of higher R&D and a lower product gross margin[21]. 2026 is the first year of the collaboration step-up; if pipeline and launch spending absorb all of it, profit growth will still depend on whether new drugs launch and scale rather than on the Dupixent share.

Second-quarter figures give a starting point that already carries several one-off costs. Second-quarter GAAP operating income rose 20% to $1.294 billion, with R&D up 15% to $1.632 billion, acquired in-process R&D of $127 million and SG&A up 4% to $662 million[9]; cost of goods sold was $361 million, including $69 million of interruption-related costs, and the GAAP gross margin on net product sales was 78%[27]. In July the company narrowed full-year guidance to GAAP R&D of $6.500 billion to $6.635 billion and GAAP SG&A of $2.830 billion to $2.960 billion, and raised the GAAP gross margin on net product sales to 78%-79%[3]; after first-half R&D of $3.175 billion and SG&A of $1.310 billion, that leaves about $1.66 billion to $1.73 billion of R&D and about $760 million to $830 million of SG&A per quarter in the second half. In October the company disclosed third-quarter acquired in-process R&D of about $22 million, far below the second quarter[4].

Whether profit rises by the full amount depends on the relative size of three forces: revenue, cost of sales and the timing of expenses. The end of the collaboration deduction and lower acquired R&D create about $360 million of favorable change across revenue and expenses; with Limerick back at normal output, the product gross margin has room to recover[8]; at the same time Phase 3 trials in Factor XI, obesity and C5 and launch preparation for cemdisiran push up R&D and SG&A, and the FDA target action date for cemdisiran in generalized myasthenia gravis is November 2026[47]. An alternative reading is that the second-half increase implied by full-year expense guidance is concentrated in the fourth quarter, making third-quarter operating income look stronger than the step-up alone; it is also possible that a faster U.S. EYLEA decline absorbs part of the collaboration gain. The per-quarter expense figures for the second half are averages derived from full-year guidance minus the first half, and the company has not given a quarterly split.

The third-quarter report needs operating income and the three cost lines to land in the expected places at the same time. If GAAP operating income is at least $1.546 billion, the GAAP product gross margin returns above 80% with no interruption-related costs, and R&D falls within about $1.66 billion to $1.73 billion for the quarter, the step-up has largely stayed in profit[3]. Operating income below the second quarter's $1.294 billion would mean the expense step-up has consumed the collaboration step-up, and a GAAP product gross margin below 78% would mean manufacturing costs have not normalized after Limerick's recovery. Whether SG&A exceeds about $825 million and whether the company changes full-year expense guidance would also change the reading of second-half profit.

Risks and Falsifiers

U.S. drug pricing policy is the first risk to Regeneron's net product prices. In April 2026 the company agreed with the U.S. government to supply certain wholly owned products to Medicaid at Most-Favored-Nation prices and to price certain future medicines in the U.S. at or below those prices, in exchange for three years of tariff relief[35]; the EYLEA franchise is reimbursed mainly by Medicare, and the company also faces civil proceedings joined by the U.S. Department of Justice[48]. This risk works directly on the net prices and rebates behind net product sales, where the EYLEA HD net price already declined in 2025[33], and on the U.S. pricing of future drugs. If the third-quarter report shows no net price cut or new rebate accrual tied to the Most-Favored-Nation agreements, and the EYLEA HD net price decline does not widen, this risk should be marked down.

Heavy concentration in customers and partners makes timing gaps between revenue recognition and cash collection likely. Two wholesalers accounted for 45% and 32% of gross product revenue in the second quarter of 2026[49], and about half of revenue depends on quarterly Dupixent settlements from Sanofi[19]. The concentration shows up in receivables: $6.565 billion at the end of June against $5.741 billion at the start of the year[28], while first-half operating cash flow fell $298 million year over year[26]. If third-quarter receivables grow no faster than revenue and operating cash flow returns to year-over-year growth, collections are not a problem.

Slower Dupixent growth and new competing drugs would directly weaken Regeneron's largest profit source. Management has already flagged slower Dupixent growth in the second half[42], while JAK inhibitors and several antibodies with new mechanisms compete in atopic dermatitis, asthma and COPD[32]. At a profit share of about 35% to 37%, each $100 million change in Dupixent sales moves Regeneron's revenue by about $35 million to $37 million, almost all of it operating income. If third-quarter Dupixent global sales grow at least 30% year over year and the pre-deduction share stays at or above 35%, this risk has not materialized.

A wave of biosimilar launches would squeeze both U.S. self-sold revenue and the Bayer share outside the U.S. The annual report anticipates more EYLEA biosimilars launching in the U.S. in the second half of 2026, with launches abroad proceeding country by country[34]; on the second-quarter call management also acknowledged the upcoming launch of multiple aflibercept 2 mg biosimilars[50]. The exposed lines are U.S. EYLEA HD and EYLEA net product sales ($1.009 billion in the second quarter) and Bayer collaboration revenue ($276 million in the second quarter, down 33%)[25]. If third-quarter U.S. EYLEA HD net sales grow at least 10% sequentially, the U.S. franchise total is at least $1.009 billion and the pre-filled syringe keeps its year-end approval target, the concern eases.

Expanding pipeline spending with uncertain returns is the long-term risk weighing on operating income. 2026 GAAP R&D guidance of $6.500 billion to $6.635 billion is about 11% to 13% above 2025's $5.850 billion[3]; the Phase 3 trial of fianlimab in first-line melanoma missed its primary progression-free survival endpoint in May[47], and program-level R&D disclosure shows rising spending across several programs[51]. The Sixth Amendment also makes Regeneron responsible for development costs on the new antibodies above a budget cap[4]. If third-quarter R&D and SG&A both fall within the ranges implied by guidance and operating income is at least $1.546 billion, this risk has not materialized this quarter.

What to Watch Next

• Dupixent profit step-up: Regeneron's recognized Sanofi profit share was $2.033 billion in the second quarter ($2.286 billion before the deduction)[6]. At least $2.286 billion with a zero deduction confirms the step-up; below $2.033 billion falsifies it.
• Dupixent growth and share: second-quarter global sales were $5.998 billion, up 38%, with a 36.8% share[39]. Growth of at least 30% with a share of at least 35% confirms; a share below 34% falsifies.
• EYLEA HD conversion: U.S. EYLEA HD net sales were $596 million in the second quarter, up 27% sequentially[25]. Sequential growth of at least 10% (about $656 million) confirms; below 5% falsifies.
• EYLEA and the franchise total: U.S. EYLEA was $412 million and the franchise $1.009 billion. A sequential EYLEA decline within 15% and a franchise of at least $1.009 billion confirm; a decline above 20% falsifies. Watch for new U.S. biosimilar launches.
• Pre-filled syringe and Bayer: the year-end approval target and a second-quarter Bayer share of $227 million[45]. Keeping the target and a stable share confirm.
• Operating leverage: GAAP operating income was $1.294 billion in the second quarter[9]. At least $1.546 billion confirms; below $1.294 billion falsifies.
• Gross margin and expenses: 78% in the second quarter against 78%-79% full-year guidance[3]. A margin above 80% confirms; below 78% falsifies.

Conclusion

Regeneron's business is driven by two forces moving in opposite directions: collaboration profit from Dupixent is accelerating while the original EYLEA shrinks quickly under biosimilar pressure. Second-quarter revenue rose 17% to $4.291 billion, and Sanofi collaboration revenue already makes up half[25]; at the end of June the company held $17.82 billion of cash and marketable securities against less than $2 billion of long-term debt[28]. The third quarter is the first after the development balance was repaid, and the central unresolved relationship is whether, with the roughly $250 million deduction gone and Limerick back in production, operating income can rise above the second quarter's $1.294 billion by the full step-up despite a continuing EYLEA decline and higher expenses.

Between the second-quarter report and mid-October, the outside coverage that could be found consisted mainly of news recaps of the second-quarter results and the October 1 Sanofi collaboration expansion (STAT, Fierce Biotech, Reuters and others), blogs focused on share-price models, and brokers' changes in their stock views. None of it could both be checked against its original text and offer an independent judgment on the three debates above, so no outside interpretation is summarized here; readers can only judge from the company's own filings and call remarks, which is a clear coverage gap.

If the third-quarter report delivers three results together, namely a Sanofi profit share of at least $2.286 billion with a share above 35%, U.S. EYLEA HD sequential growth of at least 10% that stops the franchise total from falling, and GAAP operating income of at least $1.546 billion with a product gross margin back above 80%, then the collaboration step-up is converting fully into profit and the current understanding of Regeneron is materially strengthened. Conversely, a share falling below 34%, a sequential EYLEA decline above 20%, or operating income below the second-quarter level would mean the Dupixent gain is being absorbed by EYLEA losses and pipeline spending, and the current understanding should be materially weakened.

Sources

[1] Drillr earnings calendar (updated 2026-10-17) · REGN 2026-10-30 call · 2026-10-17 · Drillr earnings calendar

[2] REGN 8-K filed 2026-07-30 · 2Q26 results headline · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

[3] REGN 8-K filed 2026-07-30 · 2026 financial guidance July 2026 · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

[4] REGN 8-K filed 2026-10-06 · Sixth Amendment with Sanofi, settlement and 3Q26 IPR&D · 2026-10-06 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/tm2627077d1_8k.htm

[5] Drillr analyst_financial_estimates (updated 2026-10-16) · REGN quarter ending 2026-09-30 · 2026-10-16 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[6] REGN 10-Q filed 2026-07-30 · Sanofi profit share and development balance repayment 2Q26 · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm

[7] REGN 10-Q filed 2026-07-30 · EYLEA biosimilar competition risk 2Q26 · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm

[8] REGN 8-K filed 2026-07-30 · 2Q26 operating expenses and gross margin · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

[9] REGN 8-K filed 2026-07-30 · 2Q26 statements of operations · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

[10] REGN 10-K filed 2026-02-04 · business overview · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[11] REGN 10-K filed 2026-02-04 · employees · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[12] REGN 10-K filed 2026-02-04 · manufacturing and commercial operations · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[13] REGN 10-K filed 2026-02-04 · dependence on EYLEA HD and Dupixent · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[14] REGN 10-K filed 2026-02-04 · revenues by product and collaborator 2023-2025 · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[15] REGN 10-K filed 2026-02-04 · global net product sales of Regeneron-discovered products 2025 · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[16] REGN 10-K filed 2026-02-04 · Libtayo royalty to Sanofi · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[17] REGN 10-K filed 2026-02-04 · customer concentration and receivables · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[18] REGN 10-K filed 2026-02-04 · Sanofi collaboration revenue and Dupixent profit share 2023-2025 · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[19] REGN 10-Q filed 2026-07-30 · Sanofi collaboration terms and contract balances · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm

[20] REGN 10-K filed 2026-02-04 · Bayer collaboration revenue 2023-2025 · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[21] REGN 10-K filed 2026-02-04 · operating expenses and headcount 2023-2025 · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[22] REGN 10-K filed 2026-02-04 · cost of goods sold and gross margin on net product sales 2023-2025 · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[23] REGN 10-K filed 2026-02-04 · consolidated cash flows: capex and repurchases 2023-2025 · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[24] REGN 8-K filed 2026-04-29 · 1Q26 results headline and revenue table · 2026-04-29 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm

[25] REGN 8-K filed 2026-07-30 · 2Q26 revenue table and drivers · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

[26] REGN 10-Q filed 2026-07-30 · liquidity, cash flows and capex plan 2026 · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm

[27] REGN 8-K filed 2026-07-30 · 2Q26 non-GAAP reconciliation and free cash flow · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

[28] REGN 8-K filed 2026-07-30 · balance sheet June 30, 2026 and capital allocation · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

[29] REGN 10-K filed 2026-02-04 · Sanofi and Bayer development balance terms · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[30] REGN 8-K filed 2026-07-30 · 2Q26 collaboration revenue table · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

[31] REGN 10-K filed 2026-02-04 · liquidity, cash flows and 2026 capex plan · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[32] REGN 10-K filed 2026-02-04 · competitors to EYLEA, Dupixent and Libtayo · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[33] REGN 10-K filed 2026-02-04 · EYLEA HD and EYLEA net product sales drivers 2025 · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[34] REGN 10-K filed 2026-02-04 · EYLEA biosimilar competition risk · 2026-02-04 · 10-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm

[35] REGN 8-K filed 2026-04-29 · U.S. government pricing agreements and Samsung settlement · 2026-04-29 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm

[36] REGN 8-K filed 2026-04-29 · EYLEA HD dosing extension and pre-filled syringe status · 2026-04-29 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm

[37] REGN Q2 2026 earnings call 2026-07-30 · segment performance · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[38] REGN 10-Q filed 2026-07-30 · EYLEA HD pre-filled syringe and U.S. government agreements · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm

[39] REGN 8-K filed 2026-07-30 · 2Q26 net product sales of Regeneron-discovered products · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

[40] REGN 8-K filed 2026-07-30 · CFO on Sanofi Development Balance and capital deployment · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

[41] REGN Q1 2026 earnings call 2026-04-29 · guidance · 2026-04-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[42] REGN Q2 2026 earnings call 2026-07-30 · guidance · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[43] REGN 10-Q filed 2026-07-30 · net product sales drivers 2Q26 · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm

[44] REGN 8-K filed 2026-04-29 · 1Q26 EYLEA HD inventory and unit demand · 2026-04-29 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm

[45] REGN 10-Q filed 2026-07-30 · Bayer profit share on EYLEA outside the U.S. 2Q26 · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm

[46] REGN Q2 2026 earnings call 2026-07-30 · Q&A on Sanofi follow-ons and pre-filled syringe · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[47] REGN 8-K filed 2026-07-30 · 2Q26 pipeline: cemdisiran, fianlimab, Factor XI · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

[48] REGN 8-K filed 2026-07-30 · forward-looking risks: pricing agreements and DOJ proceedings · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm

[49] REGN 10-Q filed 2026-07-30 · customer concentration 2Q26 · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm

[50] REGN Q2 2026 earnings call 2026-07-30 · stated risks · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[51] REGN 10-Q filed 2026-07-30 · R&D expenses by program 2Q26 · 2026-07-30 · 10-Q · https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm